Physician profile
Robyn Bryde
NPI 1730512369
$27,432.86
in general payments reported to CMS, 2019-2025
14 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $224 · 2023: $262 · 2024: $437 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $9,660 · Food and Beverage: $1,160 · Travel and Lodging: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,810.00 |
| Consulting Fee | $9,660.00 |
| Food and Beverage | $1,160.31 |
| Travel and Lodging | $578.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26,662.85 | 2023-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $224.09 | 2022 | |
| Novartis Pharmaceuticals Corporation | $158.79 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $67.31 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $50.84 | 2023-2024 | Verquvo |
| Irhythm Technologies, INC. | $47.75 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Kiniksa Pharmaceuticals International, Plc | $45.35 | 2024 | Arcalyst |
| Amgen INC. | $31.88 | 2023-2024 | Repatha |
| Novo Nordisk INC | $31.63 | 2023 | Rybelsus, Ozempic |
| Lexicon Pharmaceuticals, INC. | $30.59 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.96 | 2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $21.47 | 2023 | |
| Genzyme Corporation | $21.43 | 2023 | |
| Esperion Therapeutics, INC. | $16.92 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Bryde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.